# Design and Development of Natural-Product-Derived Nanoassemblies and Their Interactions with Alpha Synuclein

## TL;DR

Researchers designed nanoassemblies from natural products that interact with alpha-synuclein, a protein linked to Parkinson's disease, showing potential for drug delivery and therapeutic use.

## Contribution

The creation of natural-product-derived nanoassemblies that self-assemble and interact with alpha-synuclein for therapeutic applications.

## Key findings

- Nanoassemblies formed nanofibers or nanovesicles depending on the conjugate.
- Nanoassemblies effectively interacted with alpha-synuclein fibrils.
- Nanoassemblies showed high viability with microglial cells and enhanced alpha-synuclein uptake.

## Abstract

Biomimetic nanoassemblies derived from natural products are considered promising nanomaterials due to their self-assembling ability and their favorable interactions with biological molecules leading to their numerous applications as therapeutic agents or as molecular probes. In this work, we have created peptide nanoconjugates of two natural products, β-Boswellic acid (BA) and β-glycyrrhetinic acid (GH). Both BA and GH are known for their medicinal value, including their role as strong antioxidants, anti-inflammatory, neuroprotective and as anti-tumor agents. To enhance the bioavailability of these molecules, they were functionalized with three short peptides (YYIVS, MPDAHL and GSGGL) to create six conjugates with amphiphilic structures capable of facile self-assembly. The peptides were also derived from natural sources and have been known to display antioxidant activity. Depending upon the conjugate, nanofibers, nanovesicles or a mixture of both were formed upon self-assembly. The binding interactions of the nanoconjugates with α-Synuclein, a protein implicated in Parkinson’s disease (PD) was examined through in silico studies and FTIR, circular dichroism and imaging studies. Our results indicated that the nanoassemblies interacted with alpha-synuclein fibrils efficaciously. Furthermore, the nanoassemblies were found to demonstrate high viability in the presence of microglial cells, and were found to enhance the uptake and interactions of α-Synuclein with microglial cells. The nanoconjugates designed in this work may be potentially utilized as vectors for peptide-based drug delivery or for other therapeutic applications.